GlassScriptPhysician profile
Christopher Edward Dittus
NPI 1154563260
$7,986.74
in general payments reported to CMS, 2019-2025
11 companies · $3,645 in 2025
The $3,645 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,570 · 2022: $148 · 2023: $2,485 · 2024: $139 · 2025: $3,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,045 · Food and Beverage: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,045.00 |
| Food and Beverage | $223.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,645.00 | 2025 | |
| Adc Therapeutics America, INC. | $2,400.00 | 2023 | |
| Beigene, LTD. | $1,457.50 | 2021 | |
| Beigene USA, INC. | $212.37 | 2021-2022 | |
| Genmab U.S., INC. | $178.62 | 2023-2024 | Epkinly |
| Ipsen Biopharmaceuticals, INC | $48.25 | 2022 | |
| Epizyme, INC. | $45.00 | 2023 | Tazverik |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Dittus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.